date:Apr 28, 2014
Neptune has obtained a patent relating to the treatment of Alzheimers.
The patent, which is the companys first to specifically target neurological conditions, is granted for the US market and is valid until 2022. The claims focus on treating Alzheimers disease by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises DHA and EPA.
Todays announcement provides additional strength to our patent estate and highlights our commitment